 SAN DIEGO, March 08, 2021 GLOBE NEWSWIRE -- AXIM Biotechnologies, Inc. OTCQB: AXIM AXIM Biotech, AXIM or the Company, an international healthcare solutions company targeting oncological and COVID-19 research, announced today that it has successfully completed point-of-care clinical trials on its much awaited ImmunoPass rapid test that semi-quantitatively measures levels of COVID-19 neutralizing antibodies to help understand COVID-19 immunity, validate vaccines effectiveness and estimate how long the vaccine will be effective in patients. 